Organon & Co. Announces Quarterly Dividend of $0.28 (NYSE:OGN)

Organon & Co. (NYSE:OGN) announced a quarterly dividend on Tuesday, August 6th, Zacks reports. Investors of record on Friday, August 16th will be paid a dividend of 0.28 per share on Thursday, September 12th. This represents a $1.12 dividend on an annualized basis and a yield of 5.73%. The ex-dividend date of this dividend is Friday, August 16th.

Organon & Co. has a payout ratio of 24.3% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Organon & Co. to earn $4.31 per share next year, which means the company should continue to be able to cover its $1.12 annual dividend with an expected future payout ratio of 26.0%.

Organon & Co. Stock Performance

NYSE:OGN traded up $0.88 during trading hours on Wednesday, reaching $19.53. 441,417 shares of the company’s stock were exchanged, compared to its average volume of 2,280,632. The firm has a market capitalization of $5.02 billion, a price-to-earnings ratio of 4.56, a P/E/G ratio of 1.01 and a beta of 0.85. The company has a 50-day moving average of $20.82 and a 200 day moving average of $19.28. The company has a quick ratio of 1.15, a current ratio of 1.65 and a debt-to-equity ratio of 181.35. Organon & Co. has a 1-year low of $10.84 and a 1-year high of $24.08.

Organon & Co. (NYSE:OGN) last released its earnings results on Tuesday, August 6th. The company reported $1.12 EPS for the quarter, topping the consensus estimate of $1.08 by $0.04. Organon & Co. had a net margin of 16.50% and a negative return on equity of 360.57%. The company had revenue of $1.61 billion during the quarter, compared to analysts’ expectations of $1.61 billion. During the same quarter last year, the business earned $1.31 EPS. The business’s revenue was down .1% on a year-over-year basis. Research analysts anticipate that Organon & Co. will post 4.25 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on OGN. Piper Sandler increased their price target on shares of Organon & Co. from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Monday, April 29th. The Goldman Sachs Group increased their price target on shares of Organon & Co. from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Friday, May 3rd.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.